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Background: Extrapulmonary small cell carcinomas have been reported in a variety of organs, and their incidence
in the genitourinary tract is second only to that in the gastrointestinal tract. To date, however, only a few cases of
small cell carcinoma of the ureter have been reported. Because the extreme rarity of this type of carcinoma, its
clinical behaviour, diagnostic methods, and effective treatment modalities have not yet been determined.
Case presentation: A 59-year-old man presented with a 1-month history of painless gross haematuria. Urine
cytopathology revealed a urothelial carcinoma and computed tomography revealed left hydronephroureterosis
with a distal ureteral stone and a mildly enhanced fungating mass just below the stone-impacted site. The
preoperative TNM stage was T2N0M0. The patient underwent simultaneous diagnostic ureterorenoscopy and left
laparoscopic nephroureterectomy with bladder cuff resection. Gross examination showed a 3.5 × 3.0 × 0.8 cm
white, partly yellow mass in the left distal ureter. Light microscopy showed a small cell carcinoma, overlaid on a
urothelial carcinoma in situ, invading the ureter and external lateral resection margins. The small cell carcinoma was
diffusely positive for neuron-specific enolase, and exhibited focal positivity for CD 56, synaptophysin, chromogranin
and cytokeratin 20. The patient was treated with adjuvant chemotherapy, consisting of cisplatin and etoposide, and
radiation therapy, and has been well, without evidence of tumour recurrence or metastasis in the 10 months after
surgery.
Conclusion: Small cell carcinoma of the ureter is rare. Although its clinical behaviour and diagnostic modalities
have not been determined and it has yet to be diagnosed immunohistopathologically, multimodality treatment
including surgery, chemotherapy and radiotherapy may improve patient survival.
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Although most small cell carcinomas (SCCs) originate in
the pulmonary system, extrapulmonary SCCs (ESCCs)
have been reported in a variety of organs [1], with genito-
urinary ESCCs being second in incidence only to gastro-
intestinal ESCCs [2]. ESCCs of the ureter are exceedingly
rare, with only a few individual cases reported in the lit-
erature [3,4]. The histogenesis of this tumour remains un-
certain, although several hypotheses have been suggested
[5,6]. Moreover, owing to its rarity, its clinical behaviour
and appropriate treatment have not been well established.* Correspondence: hds@dreamwiz.com
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reproduction in any medium, provided the orWe describe the clinical characteristics, pathological fea-
tures and immunohistochemical findings of a primary ma-
lignant SCC combined with urothelial carcinoma.
Case presentation
In December 2011, a 59-year-old man with an unremark-
able medical history presented at the outpatient clinic with
a 1-month history of painless gross haematuria. He did
not complain of voiding symptoms, such as frequency,
hesitancy or dysuria. He had a smoking history of one
pack (Cigarettes, 20/pack) per day for 30 years, but he de-
nied having any respiratory symptoms. No remarkable
findings were noted on physical examination, and most la-
boratory tests yielded results within normal limits. How-
ever, the patient’s serum creatinine concentration wasd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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urinary cytopathology indicated a urothelial carcinoma.
Chest radiography showed an old tuberculosis scar, and
plain radiography of the kidneys, ureter and urinary blad-
der showed a radio-opaque area in the left pelvic cavity.
Abdominal computed tomography (CT) revealed a right
simple renal cyst, left hydronephroureterosis, a stone in
the left distal ureter, and a mildly enhanced, fungating mass
lesion just below the stone-impacted site (Figure 1A,B)
but no evidence of pelvic lymph node enlargement. Cysto-
scopic examination showed a bloody urine flow in the left
ureteral orifice, but no mass-like lesion.
On the basis of cystoscopic examination, imaging findings
and urinary cytopathology, a urothelial cell carcinoma of the
ureter, TNM stage T2N0M0, was diagnosed. We therefore
performed a diagnostic ureterorenoscopy, followed immedi-
ately by laparoscopic left nephroureterectomy with bladder
cuff resection. The ureterorenoscopy showed a huge, round,
fungating mass with a smooth surface without papillary
characteristics, filling the lumen of the left distal ureter
(Figure 1C). Frozen section evaluation of a biopsy sample
showed atypical urothelial cells, findings consistent with a
urothelial carcinoma. Pathological examination of the
tumour, removed by laparoscopic left nephroureterectomy
with bladder cuff resection, showed an SCC combined
with a urothelial cell carcinoma in the ureter. A bone scan
and positron emission tomography showed no evidence of
metastasis or remnant cancer.
After surgery, the patient was treated with four cycles of
chemotherapy, consisting of 100 mg/m2 etoposide on days
1, 2, and 3 and 75 mg/m2 cisplatin on day 1, every 3 weeks.
The patient also received external radiation therapy at the
site of the left ureteral mass, consisting of 180 cGy per day,
5 times per week, up to a total of 30 fractions (5400 cGy)
over 44 days. The patient tolerated adjuvant chemotherapy
and radiation therapy well, with no significant side effects
or adverse reactions, except for intermittent nausea,
vomiting and generalized myalgia. He was followed up by
urinalysis, urinary cytopathology, cystoscopy, an abdominal
CT scan and positron emission tomography. He has beenFigure 1 Radiography and ureterorenoscopy. (A,B). Abdominal comput
enhanced fungating mass lesion just below the stone-impacted site (red a
mass with a smooth surface filling the lumen of the left distal ureter.well, without evidence of tumour recurrence or metastasis,
for 10 months after surgery.
Pathology
Gross examination of the resected specimen showed a
hydronephrotic kidney with a dilated renal pelvis and
calyces, and ureteral dilation. A segment of the left ur-
eter contained a poorly defined, slightly elevated mass
(3.5 × 3.0 × 0.8 cm), which protruded into the ureteral
lumen and caused near-complete obstruction of the ur-
eter (Figure 2A). Light microscopy of the SCC area of
the specimen showed small or round cells, containing
finely granular, hyperchromatic nuclei, inconspicuous
nucleoli and scanty cytoplasm (Figure 3A). We also
observed a urothelial carcinoma in situ overlying the
SCC, with multiple foci invading the lamina propria
(Figure 3A,B). The carcinoma’s overlying mucosa was
focally denuded, with the SCC exposed to the luminal
surface (Figure 3C). In addition, the SCC invaded the
mucosa, muscularis, periureteric fat tissue and external
lateral resection margin (Figure 3D). The urothelial car-
cinoma in situ measured 15 cm in length and 3.0 cm in
circumference and was located 1.4 cm from the prox-
imal and 3.6 cm from the distal resection margin of the
ureter (Figure 2B). However, there was no evidence of
invasion of the perineural, lymphatic, renal parenchy-
mal area, or of the renal artery or renal vein.
Immunohistochemical staining showed that the SCC
was diffusely positive for neuron-specific enolase and fo-
cally positive for CD 56, synaptophysin and chromogranin
(Figure 4), whereas the urothelial cell carcinoma and
urothelial cell carcinoma in situ were negative for those
markers.
Discussion
Neuroendocrine tumours can be broadly classified as well
differentiated (true carcinoids), moderately differentiated
(atypical carcinoids) and poorly differentiated (SCCs), with
the latter including ESCCs and small cell lung cancer
(SCLC). ESCCs account for approximately 0.1% to 0.4% ofed tomogram showing a stone in the left distal ureter and a mildly
rrow). (C) Ureterorenoscopic view showing a huge, round, fungating
Figure 2 Gross examination of the specimen and mapping of
the ureter. (A) Photograph of the separated ureter showing a
poorly defined, slightly elevated mass, measuring 3.5 × 3.0 × 0.8 cm
(red arrow). Its cut surface was greyish and infiltrative, and it invaded
the periureteric fat beyond the muscularis propria. The mass was
located 3.6 cm from the distal ureteral resection margin. The
remaining mucosa was focally reddish and did not show definitive
mass. The kidney contained a unilocular small cyst, 1.1 cm in
diameter; the segment of the ureter attached to the kidney was
dilated and did not show evidence of tumour. (B) Outline of the
tumour, showing the distribution of the small cell carcinoma (blue),
urothelial cell carcinoma in situ (red), invasive urothelial cell
carcinoma (black) and dysplasia (green).
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tinal and genitourinary tracts.
Genitourinary SCCs have been reported at many sites,
including the renal pelvis [7], urinary bladder [8], ureter
[3,4], urethra [9] and prostate [10], with the most com-
mon sites being the urinary bladder and prostate. In
general, however, these tumours are rare, with SCC of
the ureter being extremely rare.
SCCs of the respiratory tract are thought to originate
from neuroendocrine cells in the bronchus called amine
precursor uptake and decarboxylation or Feyrter cells
[11] and therefore express a variety of neuroendocrine
markers. SCCs of the respiratory tract can occur in com-
bination with other histological variants of lung cancer,
including squamous cell carcinoma and adenocarcin-
oma, with the malignant tumour diagnosed and classi-
fied as a combined SCLC (c-SCLC) [12].
The histogenesis of SCCs of the ureter remains un-
clear. SCCs of the genitourinary system might originate
from multipotential epithelial cells in the genitourinary
tract [5] or from intrinsic neuroendocrine cells in the
normal genitourinary tract derived from the neural crest
during embryogenesis [6].Our patient presented with an SCC of the ureter com-
bined with high-grade urothelial carcinoma, in agreement
with the hypothesis that these tumours originate from
multipotential stem cells of the ureter. However, this SCC
of the ureter was positive for several neuroendocrine
markers, in agreement with the hypothesis that SCC origi-
nates from intrinsic neuroendocrine cells within the nor-
mal genitourinary tract derived from the neural crest
during the embryogenesis. Further evaluation is required
to clarify the pathogenesis and origin of ureteral SCCs.
Our patient visited the hospital with painless gross
haematuria. The CT showed an ill-defined ureteral mass
with a ureteral stone. The most common symptom of
SCC of the ureter is asymptomatic gross haematuria, al-
though flank pain with or without gross haematuria has
also been reported [13]. Most patients are diagnosed
with SCC of the ureter after immunohistopathological
examination of samples removed at biopsy or surgery.
SCCs can be diagnosed by determining the ultrastructure
of secretory neuroendocrine granules and immunohisto-
chemical positivity for synaptophysin and neuron-specific
enolase. Prior to immunohistopathological examination,
no clinical symptoms or imaging results can distinguish
SCC of the ureter from other conditions, such as urothelial
carcinoma, which causes asymptomatic gross haematuria
or a ureteral stone, or inflammatory disease that causes ur-
eteral obstruction. Urinary cytopathology and CT scanning
are helpful in diagnosing and preoperative planning of
treatment for asymptomatic gross haematuria. Urinary cy-
topathology can reveal evidence of the origin of the mass,
whereas CT scanning can determine its location, size and
the presence of lymph node metastasis or ureteral stones.
Our patient had a smoking history of one pack per
day for 30 years. The most frequent cause of lung can-
cer, especially SCLC, is smoking [14,15]. Smoking has
been reported to result in greater histological and gen-
etic damage to normal epithelium in patients with SCLC
than in patients with non-small cell lung cancer; allele
loss is much greater in the former than in the latter
[16]. As with SCLC, smoking might be the primary risk
factor for SCC of the genitourinary tract; patients with
SCC at any site in the urinary tract have been reported
to have a history of heavy smoking. Although SCCs of
the genitourinary tract may also occur in nonsmokers
[5,10,17], we believe that smoking is the main risk factor
for the development of ESCCs. Further clarification of
the mechanism and relationship between smoking and
ESCC is required.
Our patient underwent laparoscopic nephroureterectomy
with bladder cuff resection, followed by adjuvant chemo-
therapy with cisplatin and etoposide, and radiation therapy.
Because of the rarity of these tumours, standard treatment
has not yet been established [18]. Multimodality therapy,
including surgery, radiation and chemotherapy, has been
Figure 3 Histochemical examination of the tumour (H & E staining). (A) The area of small cell carcinoma showed small or round cells, with
finely granular, hyperchromatic nuclei, inconspicuous nucleoli and scanty cytoplasm. Nuclear moulding and cord-like appearing cells were
identified. The area of urothelial carcinoma in situ overlay the area of small cell carcinoma (200×). (B) Urothelial carcinoma cells invading the
lamina propria (100×). (C) Juxtaposition of areas of small cell carcinoma and urothelial carcinoma, showing the small cell carcinoma invading the
lamina propria as far as the periureteric adipose tissue and the overlying focal urothelial carcinoma in situ (40×). (D) Cross-sectional view of ureter
showing the small cell carcinoma invading the ureter and periureteric fat and protruding into the ureteral lumen (12.5×).
Jang et al. World Journal of Surgical Oncology 2013, 11:181 Page 4 of 5
http://www.wjso.com/content/11/1/181administered previously and has been shown to be feasible
with regard to improvement [7,8,18]. This multimodal
therapy is based on the histological similarity of SCC of
the ureter with SCLC. Effective therapeutic modalities and
treatment protocols for SCC of the ureter need to be fur-
ther evaluated.Figure 4 Immunohistochemical examination of the tumour. Immunoh
was positive for (A) neuron-specific enolase and (B) synaptophysin, (C) we
(each 400×).The prognosis of patients with SCC of the genitourinary
tract is poor, with most dying of disease within 1 year [9].
SCCs of the genitourinary tract tend to progress rapidly,
invading the regional lymph nodes, liver and other organs
[5]. The extent of disease at diagnosis is regarded as the
most sensitive predictor of survival [2]. Fortunately, ouristochemical staining showing that the area of small cell carcinoma
akly positive for CD56, and (D) focally positive for chromogranin
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rence, lymph node metastasis or distant metastasis, 10
months after surgery.
Conclusion
We report a rare case of primary malignant SCC com-
bined with urothelial carcinoma in the ureter. Although
the clinical behaviour and methods of diagnosis of SCC
of the ureter have not been established, preventing diag-
nosis prior to immunohistopathological examination of
biopsied or resected samples, multimodal therapy in-
cluding surgery, chemotherapy and radiotherapy may
improve patient survival. Urologists should be aware of
the possibility of SCC in the ureter in patients present-
ing with a ureteral mass. Further prospective studies and
standardized diagnostic criteria are needed to clarify the
epidemiology, diagnostic tools and most effective treat-
ment protocol for SCC of the ureter.
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